Abstract
Glutathione S-transferase P1 (GSTP1) belongs to a family of phase II metabolic enzymes that can detoxify the carcinogens and cytotoxic drugs by conjugating them with glutathione. Relationship of GSTP1 CpG islands hypermethylation or GSTP1 protein expression with clinicopathological characteristics of breast cancers was studied. The CpG islands hypermethylation status of GSTP1 gene was studied by methylation specific primer assay and GSTP1 expression was studied by immunohistochemistry in primary breast cancers. Of 174 breast tumors, 24 (14%) were found to have GSTP1 CpG islands hypermethylation. A significant association was found between GSTP1 CpG islands hypermethylation and large tumor size (P < 0.01) or lymph node metastases (P < 0.05). Relapse-free survival (RFS) rates of patients with GSTP1 CpG islands hypermethylation were significantly poorer than those without it (5-year RFS rates; 60 vs. 86%, P < 0.01). Multivariate analysis showed that GSTP1 CpG islands hypermethylation status was a statistically significant prognostic factor being independent of other conventional prognostic factors. Immunohistochemical study showed that here was a significant association between GSTP1 CpG islands hypermethylation and loss of GSTP1 expression (P < 0.01) but that RFS rates of patients with GSTP1 positive tumors were not significantly different from those with GSTP1 negative tumors. GSTP1 CpG islands hypermethylation, but not GSTP1 protein expression, is associated with a poor prognosis of breast cancers, suggesting that GSTP1 CpG islands hypermethylation has a potential to serve as a clinically useful prognostic factor.
Similar content being viewed by others
Abbreviations
- LN:
-
Lymph node
- ER:
-
Estrogen receptor
- PgR:
-
Progesterone receptor
References
Coles BF, Kadlubar FF (2003) Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs? Biofactors 17:115–130
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P, Kensler TW (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98:3410–3415
Cairns J, Wright C, Cattan AR, Hall AG, Cantwell BJ, Harris AL, Horne CH (1992) Immunohistochemical demonstration of glutathione S-transferases in primary human breast carcinomas. J Pathol 166:19–25
Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG (2004) GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 91:540–552
Henderson CJ, Smith AG, Ure J, Brown K, Bacon EJ, Wolf CR (1998) Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc Natl Acad Sci USA 95:5275–5280
Brotherick I, Shenton BK, Egan M, Cunliffe WE, Browell DA, Lunt LG, Young JR, Higgs MJ (1996) Examination of multidrug resistance in cell lines and primary breast tumours by flow cytometry. Eur J Cancer 32A: 2334–2341
Wang T, Arifoglu P, Ronai Z, Tew KD (2001) Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 276:20999–21003
Gilbert L, Elwood LJ, Merino M, Masood S, Barnes R, Steinberg SM, Lazarous DF, Pierce L, d’Angelo T, Moscow JA et al (1993) A pilot study of pi-class glutathione S-transferase expression in breast cancer: correlation with estrogen receptor expression and prognosis in node-negative breast cancer. J Clin Oncol 11:49–58
Silvestrini R, Veneroni S, Benini E, Daidone MG, Luisi A, Leutner M, Maucione A, Kenda R, Zucali R, Veronesi U (1997) Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J Natl Cancer Inst 89:639–645
Huang J, Tan PH, Thiyagarajan J, Bay BH (2003) Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 16:558–565
Su F, Hu X, Jia W, Gong C, Song E, Hamar P (2003) Glutathion S transferase pi indicates chemotherapy resistance in breast cancer. J Surg Res 113:102–108
Parrella P, Poeta ML, Gallo AP, Prencipe M, Scintu M, Apicella A, Rossiello R, Liguoro G, Seripa D, Gravina C, Rabitti C, Rinaldi M, Nicol T, Tommasi S, Paradiso A, Schittulli F, Altomare V, Fazio VM (2004) Nonrandom distribution of aberrant promoter methylation of cancer-related genes in sporadic breast tumors. Clin Cancer Res 10:5349–5354
Shinozaki M, Hoon DS, Giuliano AE, Hansen NM, Wang HJ, Turner R, Taback B (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. Clin Cancer Res 11:2156–2162
Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG (1998) Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58:4515–4518
Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD (1995) Fifth international conference on adjuvant therapy of breast cancer, St Gallen, March 1995. International consensus panel on the treatment of primary breast cancer. Eur J Cancer 31A:1754–1759
Adjuvant Therapy of Primary Breast Cancer (1998) 6th international conference. Olma Messen, St. Gallen, February 25–28, 1998. Abstracts. Eur J Cancer 34 (Suppl 1):S3–S45
Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821–9826
Jeronimo C, Costa I, Martins MC, Monteiro P, Lisboa S, Palmeira C, Henrique R, Teixeira MR, Lopes C (2003) Detection of gene promoter hypermethylation in fine needle washings from breast lesions. Clin Cancer Res 9:3413–3417
Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, Cairns P (2004) Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 10:28–32
Bernardini S, Miano R, Iori R, Finazzi-Agro E, Palmieri G, Ballerini S, Angeloni C, Orlandi A, Bellincampi L, Cortese C, Federici G (2004) Hypermethylation of the CpG islands in the promoter region of the GSTP1 gene in prostate cancer: a useful diagnostic and prognostic marker?. Clin Chim Acta 350:181–188
Chan QK, Khoo US, Chan KY, Ngan HY, Li SS, Chiu PM, Man LS, Ip PP, Xue WC, Cheung AN (2005) Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma. J Mol Diagn 7:8–16
Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH (2003) Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 163:1371–1378
Bellamy CO, Harrison DJ (1994) Evaluation of glutathione S-transferase Pi in non-invasive ductal carcinoma of breast. Br J Cancer 69:183–185
Peters WH, Roelofs HM, van Putten WL, Jansen JB, Klijn JG, Foekens JA (1993) Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. Br J Cancer 68:86–92
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Arai, T., Miyoshi, Y., Kim, S.J. et al. Association of GSTP1 CpG Islands Hypermethylation with Poor Prognosis in Human Breast Cancers. Breast Cancer Res Treat 100, 169–176 (2006). https://doi.org/10.1007/s10549-006-9241-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9241-9